Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy
Status
Conditions
Study type
Funder types
Identifiers
Details and patient eligibility
About
This research study is looking at people with cancer of the pancreas to find clinical factors that can explain the presence of genetic mutations
Full description
This research is being done to identify which pancreatic cancer patients should undergo genetic evaluation. A patient's personal and family history of cancer is the information typically used to make this decision, but there are currently no accurate, evidence-based guidelines that exist to help doctors use this information to make a decision.
The investigators hope that by testing all new pancreatic cancer patients, they can determine which clinical factors predict for genetic mutations in order to create a risk assessment tool.
The investigators want to determine which patients with pancreatic cancer will benefit from genetic testing. To do so, the investigators will offer all patients with pancreatic cancer in the Dana-Farber Gastrointestinal Oncology clinic referral for genetic evaluation. At the Cancer Genetics and Prevention clinic appointment, the provider will review the patient's personal and familial history of cancer and offer genetic testing.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Diagnosis of pancreatic ductal adenocarcinoma
- Signed initial informed consent
- Participant agrees to genetic counseling
Exclusion criteria
- Prospective participant unable to sign informed consent based on referring physician recommendation.
- Patient has neuroendocrine pancreatic tumor
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal